Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michaela Fontenay

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
Angiogenesis|January 15, 2021
Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortalityAurélien Philippe, Richard Chocron, Nicolas Gendron, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 21, 2021
Lupus Anticoagulant Single Positivity During the Acute Phase of COVID-19 Is Not Associated With Venous Thromboembolism or In-Hospital MortalityNicolas Gendron, Marie-Agnès Dragon-Durey, Richard Chocron, et al.
Hemasphere|January 24, 2025
Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromesDavid Rombaut, Sarah Sandmann, Tobias Tekath, et al.
Haematologica|October 6, 2018
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromesSophie Park, Olivier Kosmider, Frédéric Maloisel, et al.
Cytometry. Part B, Clinical Cytometry|December 11, 2021
Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNetVincent H J van der Velden, Frank Preijers, Ulrika Johansson, et al.
Leukemia|March 31, 2022
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemiaJustine Decroocq, Rudy Birsen, Camille Montersino, et al.
Human Mutation|May 4, 2012
Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosisChristine P Diggle, David A Parry, Clare V Logan, et al.
Cytometry. Part B, Clinical Cytometry|December 20, 2022
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working GroupAnna Porwit, Marie C Béné, Carolien Duetz, et al.
Cytometry. Part B, Clinical Cytometry|December 13, 2021
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working GroupArjan A van de Loosdrecht, Wolfgang Kern, Anna Porwit, et al.
Cell Death & Disease|March 12, 2021
Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkersFrançois-Xavier Danlos, Claudia Grajeda-Iglesias, Sylvère Durand, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
Angiogenesis|January 15, 2021
Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortalityAurélien Philippe, Richard Chocron, Nicolas Gendron, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 21, 2021
Lupus Anticoagulant Single Positivity During the Acute Phase of COVID-19 Is Not Associated With Venous Thromboembolism or In-Hospital MortalityNicolas Gendron, Marie-Agnès Dragon-Durey, Richard Chocron, et al.
Hemasphere|January 24, 2025
Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromesDavid Rombaut, Sarah Sandmann, Tobias Tekath, et al.
Haematologica|October 6, 2018
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromesSophie Park, Olivier Kosmider, Frédéric Maloisel, et al.
Cytometry. Part B, Clinical Cytometry|December 11, 2021
Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNetVincent H J van der Velden, Frank Preijers, Ulrika Johansson, et al.
Leukemia|March 31, 2022
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemiaJustine Decroocq, Rudy Birsen, Camille Montersino, et al.
Human Mutation|May 4, 2012
Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosisChristine P Diggle, David A Parry, Clare V Logan, et al.
Cytometry. Part B, Clinical Cytometry|December 20, 2022
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working GroupAnna Porwit, Marie C Béné, Carolien Duetz, et al.
Cytometry. Part B, Clinical Cytometry|December 13, 2021
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working GroupArjan A van de Loosdrecht, Wolfgang Kern, Anna Porwit, et al.
Cell Death & Disease|March 12, 2021
Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkersFrançois-Xavier Danlos, Claudia Grajeda-Iglesias, Sylvère Durand, et al.
Pageof 11